|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC41
|
|
gptkbp:brand
|
gptkb:Monjuvi
|
|
gptkbp:CASNumber
|
1610762-09-8
|
|
gptkbp:combines
|
gptkb:lenalidomide
|
|
gptkbp:developedBy
|
gptkb:Incyte
gptkb:MorphoSys
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tafasitamab
|
|
gptkbp:indication
|
relapsed or refractory diffuse large B-cell lymphoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:CD19
|
|
gptkbp:mechanismOfAction
|
binds to CD19 on B cells
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
diarrhea
fatigue
cough
neutropenia
respiratory tract infection
pyrexia
peripheral edema
|
|
gptkbp:target
|
gptkb:CD19
|
|
gptkbp:UNII
|
6QY1D9Y4F1
|
|
gptkbp:usedFor
|
treatment of diffuse large B-cell lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Monjuvi
gptkb:CD19
|
|
gptkbp:bfsLayer
|
6
|